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Background: PSEN2 mutations are rare variants, and fewer than 30 different PSEN2 mutations have been found. So
far, it has not been reported in Asia.
Case presentation: PSEN2 mutation at codon 214 for predicting a valine to leucine substitution was found in a
70-year-old woman, who showed a dementia of the Alzheimer type. We did not find the mutation in 614 control
chromosomes. We also predicted the structures of presenilin 2 protein with native Val 214 residue and Leu 214
mutation, which revealed significant structural changes in the region.
Conclusion: It could be a novel mutation verified with structural prediction in a patient with Alzheimer’s disease.
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Well-known mutations associated with autosomal dom-
inant Alzheimer’s disease (AD) inheritance are amyloid
precursor protein (APP) and presenilin 1 (PSEN1) and
presenilin 2 (PSEN2) [1,2]. Previous studies have shown
several APP and PSEN1 mutations in Asian populations,
but pathogenic PSEN2 mutation has not yet been de-
scribed [3,4]. We had screened PSEN2 mutation in 90 AD
patients of two memory clinics from May to December
2012. Here, a patient of East Asian descent with AD was
found with a probable novel Val214Leu mutation at
PSEN2 exon 7.Case presentation
A seventy-year-old right-handed female has complained
progressive memory problems, which started one year
prior to the initial visit. She reported her frequent forget-
fulness of going to important meetings and had difficulties* Correspondence: seong.an@gmail.com; neuroksy@snu.ac.kr
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unless otherwise stated.in grocery shopping. She also reported in having a tremor
in her right hand for the past 20 years, persistent during
resting and forearm stretching stances, which did not pro-
gress further. She presented with slightly decreased facial
expressions, but did not show rigidity, ataxia, myoclonus,
or seizure. Since she was separated from her other family
members during the Korean War, we could not obtain her
family history. Her Korean version of Mini-Mental Status
Examination (K-MMSE) was 18 and CDR-sum of boxes
was 4.5. She also underwent neuropsychological tests
using a standardized neuropsychological battery called
the Seoul Neuropsychological Screening Battery (SNSB)
[5]. She had normal spontaneous speech and compre-
hension. Her SNSB showed digit span forward was 16.86%
ile; Korean-Boston naming test, 12.09%ile; Rey-Osterrieth
Complex Figure Test copy, 0.01%ile; calculation, < 5%ile;
Seoul Verbal Learning Test-delayed recall, 1.05%ile;
Rey-Osterrieth Complex Figure-delayed recall test, 2.09%
ile; Digit Symbol Coding, 1.15%ile; Korean Stroop test-color
reading, 11.46%ile; Controlled Oral Word Association Test,
0.01%ile. She also revealed the BPO (body part as object)
error when doing praxis test. Fist-edge-palm and alternat-
ing hand movement, motor impersistence test were nor-
mal, but Luria loop and alternating square and triangle
were deformed and perseverative. Neuropsychologicaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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was not improved by cues. In addition, she showed visuo-
spatial dysfunction and difficulty in calculation and frontal
executive function. Her brain MRI (Figure 1a) showed dif-
fuse cortical atrophy with mild white matter hyperintensi-
ties in FLAIR images, and FDG-PET (Figure 1b) revealed
bilateral temporoparietal and precuneus hypometabolism.
A diagnosis of probable AD was made. She had an
APOE ε3/4 polymorphism, but other laboratory tests
were normal.
Genetic analysis of PSEN2 and structural
prediction of mutant PSEN 2 protein
DNA was extracted from the buffy coat of the venous
blood samples using a blood DNA isolation kit (GeneAll
Inc., Seoul, South Korea). APP exon 16 and 17, PSEN 1
exon 4, 5, 6, 7, 8, and 11, PSEN 2 exon 4, 5, 6, 7, and 12,
the coding region of the PRNP gene, mutations in the
microtubule-associated protein tau (MAPT) and progra-
nulin (GRN) were amplified by PCR for genetic analysis.
A sizing-genotyping and repeat-primed PCR were per-
formed to monitor the presence of the abnormal repeat
expansions of C9orf72.
Single-strand conformation polymorphism (SSCP) [6]
and Surveyor nuclease assay kit [7] revealed alternative
migration and cleavage patterns in comparison to normal
(Figure 2a, b), strongly suggesting the presence of muta-
tion in the PCR product of PSEN 2 exon 7. All PCR prod-
ucts were sequenced for the confirmation. We found a
valine to leucine substitution (Val214Leu) at exon 7 of
PSEN2 in both patients (Figure 2c). This PSEN2 mutation
could be considered as a novel mutation, since 614 controlFigure 1 Axial FLAIR, coronal and sagittal T1 images of brain MRI (a)
(70.3 ± 1.4 yr); p < 0.001, uncorrected; extent threshold = 10 voxels) o
maps indicates the Z value magnitude, with the lowest value appearing inchromosomes (307 subjects: 140 healthy control, 90 AD,
15 mild cognitive impairment, 12 subjective memory im-
pairment, 10 frontotemporal dementia, 5 vascular cognitive
impairment, 35 unclassified patients) were also screened
for Val214Leu mutation without any evidence, in support
of the present finding. All study subjects provided written
informed consent to allow their genetic and clinical
data to be used for research purposes. The Institutional
Review Board at Chung-Ang University Hospital and
Seoul National University Bundang Hospital approved
this study.
The structures of presenilin 2 with native Val 214 resi-
due and Leu 214 mutation were generated by RaptorX
3D prediction program. Overall structural features were
identical between the native presenilin 2 with Val 214
residue and Leu mutation. However, the side-chains of
Val and Leu 214 residues reveal noticeable changes of
extending towards opposite direction. In addition, other
proceeding residues, Ile 219 and His220, revealed sig-
nificant changes in their side-chains (Figure 3).
Polymorphism Phenotyping v2 (PolyPhen 2, http://genetics.
bwh.harvard.edu/pph2/) online program for predicting the
putative pathogenic phenotype was also used to evaluate
PSEN2 Val214Leu mutation by analyzing the non-
synonymous mutations in the coding region [8]. Poly-
Phen2 compared the wild-type sequences and the mutant
sequences by using sequence-and structure-based predict-
ive features, based on maping the missense mutations to
the transcriptomes, performes protein sequence annota-
tions and structural comparisons. Next, PolyPhen 2 per-
formed a multiple alignment of sequences from different
organisms. In addition, it could provide 3D structure ofand statistical parametric maps (21 age matched control subjects
f FDG-PET (b) of the patient. The color scale of statistical parametric
dark red and the highest value in bright yellow/white.
Figure 2 Genetic analysis in finding novel Val214Leu mutation at PSEN2 exon 7. After PCR amplification of APP exon 16 and 17, PSEN 1
exon 4, 5, 6, 7, 8, and 11, PSEN 2 exon 4, 5, 6, 7, and 12, and the coding region of the PRNP gene, PCR amplicons were analysis by single-strand
conformation polymorphism (SSCP, a) and Surveyor nuclease assay (b). PCR amplicon from AD patient showed different cleavage pattern than
the normal control by nuclease, as indicated with red arrows (c). All PCR amplicons were sequenced with primers, used in PCR amplification.
Novel mutation of Val214Leu at PSEN 2at exon 7 of the patient was obtained, where GTG of Val was converted into TTG of Leu at 5′ direction
(red arrow) and CAC to CAA at 3′ direction (green arrow).
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types of datasets, HumDiv and HumVar, were available
from PolyPhen 2, which were calculated from position-
specific independent counts (PSIC) scores of normal and
mutant allele. For PSEN2 Val214Leu, the HumDiv score
was 0.972 (sensitiviy: 0.77; specificity: 0.96), which indi-
cated as probably damaging mutation with the HumVar
score of 0.836 (sensitiviy: 0.73; specificity: 0.88), as pos-
sibly damaging mutation.
Discussion and conclusion
We detected a single nucleotide polymorphism on exon
7 of PSEN2 in a patient with dementia of the Alzheimer
type. So far, a pathological PSEN2 mutation has not been
reported in Asia. Particularly, Val214Leu at PSEN2 was
not reported previously and also was not found in general
Korean population. This is suggesting as a probable novelFigure 3 Superimposed structures of presenilin 2 with native Val 214
Val 214 residue and Leu mutation were generated by RaptorX 3D prediction
changes of extending towards opposite direction (a). Green color CPK (Corey
red color indicated the Leu mutation. Other proceeding residues, Ile 219 and
colored side-chains indicated the Ile and His residues from the native form anPSEN2 mutation in association with this AD patient.
Upon structural prediction of native and mutant prese-
nilin 2 by using RaptorX program, the results revealed
significant structural changes in the region (Figure 3).
When two structures of Val 214 and Leu mutant were
superimposed, the where side-chains of Val 214 and Leu
214 were pointing to opposite direction, suggesting
drastic alterations in the region. Additional residues,
Ile219 and His220, also revealed dramatic changes, sup-
porting that Val replacement to Leu could cause overall
structures and function of presenilin 2 (unpublished re-
sult, An’s personal communication). On the other hand,
many other pathogenic mutations of Val replacement to
Leu were reported [9,10].
PolyPhen2 and other bioinformatic algorithms could
be used for predicting the pathogenic nature of novel mu-
tations or known mutations [11,12]. Since cell models andresidue and Leu mutation. The structures of presenilin 2 with native
program. The side-chains of Val and Leu 214 residues reveal noticeable
, Pauling, Koltun) indicates the side-chain of native Val residue and the
His220, revealed significant changes in their side-chains (b). Green
d red colored side-chains indicated the mutant presenilin 2.
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mations and simulations could aid in understanding the
pathogenic or non-pathogenic nature of mutations. The
prediction for PSEN2 Val214Leu by Polyphen2 provided
HumDiv and HumVars scores of 0.972 and 0.836. Hence,
These analyses suggested the PSEN2 Val214Leu mutation
could be a possibly strong damaging variant.
Multiple sequence alignment for PSEN2 was performed
in comparison with different organisms. Analysis pre-
dicted that the vertebrates, such as rhesus macaque, african
elephants pigs, dog, duck, revealed the normally codon Val
at 214. However, few organisms (invertebrates, mostly uni-
cellular organisms) revealed the alterations, Leu, Gly, Ile or
Met, at the same Val214 position. For example, Methionine,
isoleucene, or leucine were found in the Tribolium casta-
neum, Trichoplax adhaerens, and Entamoeba histolytica,
respectively. PSEN2 V214 seemed to be strongly conserved
in 115 species and mutations of Leu, Gly, Ile or Met were
found in 8 species.
AD patients who have exon-7 PSEN2 have reported
wide spectrum of cognitive and non-cognitive symptoms.
They could initially show anxiety and irritability along
with mild deficits in memory, attention, and language.
Then they could also show seizure and myoclonus. Some
patients present global cognitive impairment at first.
Exon-7 PSEN2 mutation revealed an age range of onset
between 45 and 85 years overlapping early and late onset
AD [13-15]. This could be explained by the demonstrated
tendencies of PSEN2 mutations in presenting lower pene-
trance and appearing a later and more variable age of on-
set than the other early-onset AD gene mutations [16].
Although the patient showed a multi-domain cognitive
impairment with decreased facial expression and non-
progressing right hand tremor, her significant memory im-
pairment was the initial main complaint at age 69 and
prominent temporoparietal lobe dysfunction supported by
FDG-PET, no abnormal repeat expansion of C9orf72 and
no other mutation in MAPT and GRN, which could be
clinically classified as late-onset AD. Because her family
was separated during Korean War, family history was lim-
ited. We could not find any other affected family member.
When considering diagnoses atypical AD patients, we
can do CSF Aβ 1-42 analysis or Pib-PET supporting an
AD diagnosis. Even though she did not perform CSF
and Pib-PET study, we considered the patient as probable
AD because she initially complained memory problem
confirmed with a neuropsychological test and showed
bilateral hippocampal atrophies in structural MRI and
hypometabolism of bilateral temporoparietal area and
precuneus in FDG-PET.
Even though, this report is providing limited evidence
of pathogenicity, to our knowledge, this is the first case
report of AD with this probable novel PSEN2 Val214Leu
mutation verified with structure prediction.Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompanying
images. A copy of the written consent is available for
review by the Editor of this journal.
Competing interests
The authors declare that they have no competing of interests.
Authors’ contributions
YCY: drafting/revising the manuscript for content, analysis and interpretation
of data. EB and SSAn: performing the genetic analyses, predicting presenilin
2 protein structure and interpretation of the data. HRK: preparing the
samples and drafting/revising the manuscript for content. BOC: verifying the
mutations in the general population, and interpretation of data. SYK: analysis
or interpretation of data, study supervision, obtaining funding. All authors
read and approved the final manuscript.
Authors’ information
This is a case report. This manuscript has not been published elsewhere, nor
is it under simultaneous consideration for publication elsewhere. All of the
authors and contributors have agreed to the conditions of authorship. All
authors have full access to all of the data and have the right to publish any
and all data, and each author believes that the manuscript represents honest
work. The methods section includes a statement of our institutional review
board (IRB)’s approval. This research complies with the principles of the
Declaration of Helsinki (1964). No identifying information for the patient is
included in the data reported. There are no conflicts of interest to report and
all authors adhered to ethical standards.
Acknowledgements
This research was supported by a grant of the Korea Healthcare technology
R&D Project, Ministry of Health and Welfare, Republic of Korea (HI10C2020)
and by the National Research Foundation of Korea (NRF) grant funded by
the Korea government (MEST, No. 2010-0024004).
Financial disclosure
This research was supported by a grant of the Korea Healthcare technology
R&D Project, Ministry of Health and Welfare, Republic of Korea (HI10C2020)
and by the National Research Foundation of Korea (NRF) grant funded by
the Korea government (MEST, No. 2010-0024004).
Dr. Youn YC receives a grant of the Korea Healthcare technology R&D
Project, Ministry of Health and Welfare, Republic of Korea (HI10C2020).
Dr. An SS receives the National Research Foundation of Korea (NRF) grant
funded by the Korea government (MEST, No. 2010-0024004).
M.Sc. Eva Bagyinszky reports no disclosure.
Dr. Kim HR reports no disclosure.
Dr. Choi B reports no disclosure.
Dr. Kim S reports no disclosure.
Author details
1Department of Neurology, Chung-Ang University College of Medicine,
Seoul, South Korea. 2Department of Bionano Technology, Gachon Bionano
Research Institute, Gachon University, Seongnam-si, South Korea.
3Department of Laboratory Medicine, Chung-Ang University College of
Medicine, Seoul, South Korea. 4Department of Neurology, Samsung Medical
Centre, Sungkyunkwan University, Seoul, South Korea. 5Department of
Neurology, Seoul National University Bundang Hospital, Seoul National
University College of Medicine, Seongnam, South Korea.
Received: 11 January 2014 Accepted: 9 May 2014
Published: 15 May 2014
References
1. Bertram L, Lill CM, Tanzi RE: The genetics of Alzheimer disease: back to
the future. Neuron 2010, 68:270–281.
2. Cruts M, van Duijn CM, Backhovens H, Van den Broeck M, Wehnert A,
Serneels S, Sherrington R, Hutton M, Hardy J, St George-Hyslop PH, Hofman A,
Van Broeckhoven C: Estimation of the genetic contribution of presenilin-1
Youn et al. BMC Neurology 2014, 14:105 Page 5 of 5
http://www.biomedcentral.com/1471-2377/14/105and-2 mutations in a population-based study of presenile Alzheimer
disease. Human Mole Genet 1998, 7:43–51.
3. Park HK, Na DL, Lee JH, Kim JW, Ki CS: Identification of PSEN1 and APP
gene mutations in Korean patients with early-onset Alzheimer’s disease.
J Korean Med Sci 2008, 23:213–217.
4. Thajeb P, Wang P, Chien CL, Harrigan R: Novel polymorphisms of the
amyloid precursor protein (APP) gene in Chinese/Taiwanese patients
with Alzheimer's disease. J Clin Neurosci 2009, 16:259–263.
5. Ahn HJ, Chin J, Park A, Lee BH, Suh MK, Seo SW, Na DL: Seoul
Neuropsychological Screening Battery-dementia version (SNSB-D): a useful
tool for assessing and monitoring cognitive impairments in dementia
patients. J Korean Med Sci 2010, 25:1071–1076.
6. Hayashi K: PCR-SSCP: a simple and sensitive method for detection of
mutations in the genomic DNA. PCR Methods Appl 1991, 1:34–38.
7. Kim J, Bagyinszky E, Chang YH, Choe G, Choi BO, An SS, Kim S: A novel
PSEN1 H163P mutation in a patient with early-onset Alzheimer’s disease:
clinical, neuroimaging, and neuropathological findings. Neurosci Lett
2012, 530:109–114.
8. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P,
Kondrashov AS, Sunyaev SR: A method and server for predicting
damaging missense mutations. Nat Methods 2010, 7:248–249.
9. Queralt R, Ezquerra M, Lleo A, Castellvi M, Gelpi J, Ferrer I, Acarin N, Pasarin L,
Blesa R, Oliva R: A novel mutation (V89L) in the presenilin 1 gene in a family
with early onset Alzheimer’s disease and marked behavioural disturbances.
J Neurol Neurosurg Psychiatry 2002, 72:266–269.
10. Jia J, Xu E, Shao Y, Sun Y, Li D: One novel presenilin-1 gene mutation in a
Chinese pedigree of familial Alzheimer’s disease. J Alzheimers Dis 2005,
7:119–124. discussion 173-180.
11. Cherbal F, Salhi N, Bakour R, Adane S, Boualga K, Maillet P: BRCA1 and
BRCA2 unclassified variants and missense polymorphisms in Algerian
breast/ovarian cancer families. Dis Markers 2012, 32:343–353.
12. Catucci I, Milgrom R, Kushnir A: Germline mutations in BRIP1 and PALB2
in Jewish high cancer risk families. Fam Cancer 2012, 11:483–491.
13. Finckh U, Alberici A, Antoniazzi M, Benussi L, Fedi V, Giannini C, Gal A,
Nitsch RM, Binetti G: Variable expression of familial Alzheimer
disease associated with presenilin 2 mutation M239I. Neurology
2000, 54:2006–2008.
14. Jayadev S, Leverenz JB, Steinbart E, Stahl J, Klunk W, Yu CE, Bird TD:
Alzheimer’s disease phenotypes and genotypes associated with
mutations in presenilin 2. Brain 2010, 133:1143–1154.
15. Marcon G, Di Fede G, Giaccone G, Rossi G, Giovagnoli AR, Maccagnano E,
Tagliavini F: A novel Italian presenilin 2 gene mutation with prevalent
behavioral phenotype. J Alzheimers Dis 2009, 16:509–511.
16. Tandon A, Fraser P: The presenilins. Genome Biol 2002, 3:reviews.3014.1–3014.9.
doi:10.1186/1471-2377-14-105
Cite this article as: Youn et al.: Probable novel PSEN2 Val214Leu
mutation in Alzheimer’s disease supported by structural prediction. BMC
Neurology 2014 14:105.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
